India's medical device industry and healthcare groups have formally opposed the draft Drugs, Medical Devices and Cosmetics Bill, 2026, warning that treating devices as pharmaceutical products and attaching criminal penalties to regulatory lapses could stall manufacturing, investment and innovation, ETHealthworld reported. The debate has focused on manufacturers, but the operational burden of any tightened device regime lands squarely on the hospitals, diagnostic chains and clinic groups that operate the equipment day to day.
The current framework treats medical devices under a modified drug regulation carried over from the Drugs and Cosmetics Act. The 2026 draft consolidates devices, drugs and cosmetics into a single legal instrument and introduces harsher penalties, including criminal liability, for certain regulatory failures. Industry submissions from AiMeD, MTaI and hospital associations argue that a defective infusion pump is not a defective tablet, device failures usually involve calibration, servicing, wear, software patches and user error, not a bad batch.
For a 200-bed hospital or a 40-centre diagnostic chain, the practical impact is this: expect stricter documentation obligations on device provenance, calibration cycles, service history, incident reporting and end-of-life disposal. Regulators looking to enforce a tougher law will not chase paperwork from manufacturers alone, they will ask the operator to produce a full audit trail on any device involved in an adverse event. Operators without a machine-level record today will feel the load first.
Most Indian mid-tier hospitals still maintain device inventory in a mix of Excel sheets, biomedical engineer notebooks and vendor emails. That model has already been under strain from NABH renewals, HCFI audits and TPA queries. A stricter device law raises the cost of a missing record from an inconvenience to a legal exposure.
Three failure modes recur across HODO's 500+ client outlets when operators try to keep device records in spreadsheets. First, AMC and warranty expiry dates fall off the calendar and equipment goes out of coverage without anyone noticing until it fails. Second, calibration certificates are stored on the biomedical engineer's laptop and are unrecoverable when that person leaves the organisation. Third, the link between a specific device, the patient it was used on and the operator on shift is reconstructed manually, which is exactly what a stricter regime will want to see instantly.
Under a tightened device law, the question after any incident becomes: which serial-numbered device touched this patient, when was it last calibrated, who operated it and what did the machine actually report? That chain requires three linked records, an asset register with serials, warranties and AMC status; a machine interface that captures raw device output against a patient ID; and an EMR that logs which clinician ordered the test or procedure.
Hospitals that already run a hospital information system with device interfacing get most of this chain for free. Those that do not will have to build it, quickly, and under audit pressure. The manufacturer opposition to the draft bill may soften some of the criminal-penalty language, but the direction of travel is clear: device operators will need better records, not fewer.
Groups that have already been through NABH re-accreditation or ABDM integration have a head start. A short list of practical moves is emerging from that cohort. Consolidate the biomedical asset register into the HIS instead of a parallel spreadsheet, so warranty and AMC expiries appear on the same dashboards administrators already read. Push machine outputs, analyser results, imaging metadata, monitor readings, directly into the patient record via interfacing rather than manual re-entry, so the source of every clinical data point is auditable.
Track service visits, calibration dates and part replacements against the serial number, not the department. Keep vendor documents, user manuals, service reports, incident reports, attached to the asset record so they survive staff turnover. None of this requires waiting for the final shape of the bill. It reduces TAT, cuts equipment downtime, and closes the gap that any tightened regulation will target first.
For chains, clinic groups, diagnostic networks, franchise pathology brands, the compliance load multiplies with every new outlet. A single Trivandrum centre with 40 devices is manageable in spreadsheets. Forty centres with 40 devices each is not. Operators expanding under any tightened device regime will need a system where a new centre inherits the same asset-tracking discipline on day one, not the third audit cycle. Centralised HIS deployment stops being a nice-to-have. New-centre onboarding must include the device register, AMC schedule, calibration protocol and machine interfacing setup as a single package, or each outlet drifts into its own record-keeping style. Diagnostic chains face the same problem at higher volume, because every LIS-connected analyser is itself a regulated device.
Hospitals and diagnostic groups on Healzapp already have the plumbing this regulatory shift will demand. Warranty+AMC asset tracking keeps every biomedical device on a live register with expiry alerts, so a stricter regime does not become a scramble to reconstruct records. Machine Interfacing puts raw device output straight into the patient record, giving operators the asset-to-encounter chain regulators will ask about after any incident. For groups adding centres under compliance pressure, Multi-outlet scale-up with one-click new-centre setup means the same device-tracking discipline is inherited by every new outlet from day one, not built again from scratch.
See how Healzapp handles this, book a 30-min demo.
Source of the news hook: https://health.economictimes.indiatimes.com/news/medical-devices/medical-devices-are-not-pharma-products-companies-say-while-opposing-draft-bill/133140112
See how Healzapp, Labzapp and EReazy fit your speciality in a free 30-minute demo.
Book a Free Demo